|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||18.57|
|Dividend & Yield||1.12 (2.68%)|
|1y Target Est||N/A|
Campbell, CA -based VIVUS, Inc. (VVUS) is a biopharmaceutical company developing and commercializing innovative, next-generation therapies to address unmet medical needs
AstraZeneca plc (AZN) announced top-line results from the EXSCEL study evaluating the cardiovascular (CV) safety profile of its type II diabetes drug Bydureon.
Novo Nordisk stock popped Tuesday after AstraZeneca said its Type 2 diabetes drug didn't reduce the risk of cardiovascular events in a trial.